Literature DB >> 9145878

Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.

D J Demczar1, A N Nafziger, J S Bertino.   

Abstract

Two doses of gentamicin (2 and 7 mg/kg of body weight) were administered to 11 healthy volunteers in a randomized, crossover single-dose study to compare their pharmacokinetics. Doses were infused over 1 h with a syringe infusion pump, and 14 concentrations in sera were obtained over an 8-h period. Concentration in serum versus time data were fitted to a two-compartment pharmacokinetic model. In addition, to mimic the clinical setting, subjects' data were fitted by the Sawchuk-Zaske method. Distributional and postdistributional peak concentrations, along with the last obtained concentration in serum, were utilized to compare the following pharmacokinetic variables: volume of distribution at steady state (Vss), half-life, clearance (CL), and maximum concentration in serum (Cmax). With two-compartment pharmacokinetic fitting, significant differences in distribution half-life (average, 21.8 and 41.6 min [P < or = 0.05]) and gentamicin CL (76.6 +/- 6.6 and 67.2 +/- 4.2 ml/min/1.73 m2 [P < or = 0.001]) were found between traditional-dose and high-dose groups, respectively. When the data for concentrations in sera were fitted to a one-compartment pharmacokinetic model by using either the distributional or the postdistributional Cmax, statistically significant differences (P < or = 0.001) were found between Vss, half-life, CL, and Cmax values for both dosage groups. The results show that the pharmacokinetics of gentamicin at a large dose differ significantly from those at the traditional dose. This information has direct implications for once-daily aminoglycoside (ODA) literature when the Cmax values reported are distributional and therefore show falsely high Cmax/MIC ratio estimates. In addition, ODA nomogram dosing tools developed with distributional Cmax values are probably inaccurate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9145878      PMCID: PMC163859     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Once-daily dosing decreases renal accumulation of gentamicin and netilmicin.

Authors:  G A Verpooten; R A Giuliano; L Verbist; G Eestermans; M E De Broe
Journal:  Clin Pharmacol Ther       Date:  1989-01       Impact factor: 6.875

3.  Prediction of blood levels after multiple doses from single-dose blood level data: data generated with two-compartment open model analyzed according to the one-compartment open model.

Authors:  J G Wagner; C M Metzler
Journal:  J Pharm Sci       Date:  1969-01       Impact factor: 3.534

4.  Pharmacokinetics of gentamicin after i.v. infusion or iv bolus.

Authors:  F Meunier; P Van der Auwera; H Schmitt; V de Maertelaer; J Klastersky
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

5.  Amikacin once daily: a new dosing regimen based on drug pharmacokinetics.

Authors:  R Maller; B M Emanuelsson; B Isaksson; L Nilsson
Journal:  Scand J Infect Dis       Date:  1990

6.  Once versus thrice daily gentamicin in patients with serious infections.

Authors:  J M Prins; H R Büller; E J Kuijper; R A Tange; P Speelman
Journal:  Lancet       Date:  1993-02-06       Impact factor: 79.321

7.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Authors:  R D Moore; P S Lietman; C R Smith
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

8.  Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin.

Authors:  P M Tulkens
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

Review 9.  Pharmacokinetic evaluation of single daily dose amikacin.

Authors:  P Van der Auwera
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

10.  Pharmacokinetics of intravenously administered isepamicin in men.

Authors:  C C Lin; E Radwanski; C Korduba; M Cayen; M Affrime
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more
  21 in total

1.  Pharmacokinetics of gentamicin C(1), C(1a), and C(2) in beagles after a single intravenous dose.

Authors:  N Isoherranen; E Lavy; S Soback
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.

Authors:  Kim Credito; Gengrong Lin; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

3.  Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients.

Authors:  N Krivoy; S Postovsky; R Elhasid; M W Ben Arush
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

Review 4.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

5.  Extended-interval aminoglycoside therapy for adult patients with febrile neutropenia: a systematic review.

Authors:  Sarah N Stabler; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2011-05

6.  Effects of obesity and sex on antimicrobial pharmacokinetics and acute kidney injury: validation of a preclinical model.

Authors:  Manjunath P Pai; Wen Zhen Chen; Adinoyi Garba; Huadong Cui; Barbara Zaffo; Hassan A N El-Fawal; Shaker A Mousa
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

7.  Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs).

Authors:  Juwon Yim; Jordan R Smith; Nivedita B Singh; Seth Rice; Kyle Stamper; Cristina Garcia de la Maria; Arnold S Bayer; Nagendra N Mishra; José M Miró; Truc T Tran; Cesar A Arias; Paul Sullam; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

Review 8.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Population pharmacokinetics of gentamicin and dosing optimization for infants.

Authors:  Susanna E Medellín-Garibay; Aída Rueda-Naharro; Silvia Peña-Cabia; Benito García; Silvia Romano-Moreno; Emilia Barcia
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

10.  Extended Interval Tobramycin Pharmacokinetics in a Pediatric Patient With Primary Ciliary Dyskinesia Presenting With an Acute Respiratory Exacerbation.

Authors:  Kristi L Higgins; Cady Noda; Jeremy S Stultz
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.